Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

Abstracts that are incomplete or received after the deadline will not be considered. All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA staff ...

Affimed N.V., a clinical-stage immuno-oncology company, announced that an abstract on its phase 2 LuminICE-203 study involving the innate cell engager acimtamig in combination with AlloNK has been ...

LONG BEACH, Calif.--(BUSINESS WIRE)--The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, announced today that a video poster abstract presentation on the efficacy and safety ...

Proposals that are incomplete or received after the deadline will not be considered. All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA staff ...

The Hopkins Center for Health Disparities Solutions (HCHDS) at the Johns Hopkins Bloomberg School of Public Health is now accepting abstracts for poster presentations at the fourth annual HCHDS ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...

The Biennial Conference on Chemical Education 2026 (BCCE 2026) is seeking abstract submissions from educators, researchers, and practitioners. This includes for in-person oral presentations and global ...

AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a ...

For more and to view the abstract, visit the AACR Annual Meeting website. As previously announced, on December 11, 2024, TuHURA entered into a definitive agreement with Kineta, Inc. (OTC Pink: KANT) ( ...

For more information about the event, please visit the meeting website. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of ...